Skip to main content
. 2021 Nov 18;601(7893):410–414. doi: 10.1038/s41586-021-04231-6

Fig. 3. Protective efficacy of CV2CoV.

Fig. 3

Negative-control animals (sham) and animals (n = 6 per group) vaccinated on day 0 and day 28 with 12 µg of CVnCoV or CV2CoV were challenged with 1.0 × 105 TCID50 of SARS-CoV-2 (USA-WA1/2020) via the intranasal and intratracheal routes. a, b, BAL (a) and nasal swab (b) samples collected on days 1, 2, 4, 7 and 10 after challenge were analysed for levels of replicating virus by RT–PCR specific for sgRNA. Thin black lines represent individual animals and thick red lines depict the median; the dashed line shows the limit of detection.

Source data